SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

ナノメディシン市場調査レポート

Nanomedicine Market Research Report

ナノメディシン市場調査レポート : モダリティ（治療と診断）、用途（ドラッグデリバリー、画像診断、ワクチン、再生医療、インプラント）、適応症（腫瘍疾患、感染症、心血管疾患、整形外科疾患、神経疾患、泌尿器疾患、眼科疾患、免疫疾患およびその他）、分子タイプ（ナノ粒子 [アルブミン粒子、無機ナノ粒子、脂質ナノ粒子、リポソームなど]、ナノシェル、ナノチューブ、ナノデバイス）および地域（北米、ヨーロッパ、アジア太平洋、その他世界） - 2032年までの予測
Nanomedicine Market Research Report: Information by Modality (Treatments and Diagnostics), by Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants), and by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others), by Molecule Type (Nanoparticles [Albumin Particles, Inorganic Nanoparticles, Lipid Nanoparticle, Liposomes, and Others], Nanoshells, Nanotubes, and Nanodevices), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

商品番号 : SMB-69946

出版社arket Research Future
出版年月2024年11月
ページ数149
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

Market Overview

In 2023, the nanomedicine market was estimated to be worth USD 252.97 billion. During the forecast period (2024-2032), the Nanomedicine Market industry is anticipated to experience a compound annual growth rate (CAGR) of 12.48%, increasing from USD 273.79 billion in 2024 to USD 819.84 billion by 2032.

2023 年のナノ医療市場は 2,529 億 7,000 万米ドルの価値があると推定されています。予測期間中（2024年から2032年）、ナノメディシン市場業界は12.48％の年間複合成長率（CAGR）を経験し、2024年の2,737億9,000万米ドルから2032年までに8,198億4,000万米ドルに増加すると予想されます。

The global market is experiencing growth due to the increasing prevalence of a variety of diseases worldwide and the agreements that are associated with the development of nanomedicine products.

Market segment insights

The Nanomedicine Market has been divided into treatments and diagnostics based on modality.

The Nanomedicine Market has been segmented into the following categories: drug delivery, diagnostic imaging, vaccines, regenerative medicine, and implants.

The Nanomedicine Market has been segmented into oncological diseases, infectious diseases, cardiovascular diseases, orthopedic diseases, neurological diseases, urological diseases, ophthalmological diseases, immunological diseases, and others, based on indication.

The Nanomedicine Market has been segmented into nanoparticles, nanoshells, nanotubes, and nanodevices based on the type of molecule.

Regional Perspectives

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the Rest of the World. North America held the largest market share of over 38.14% in 2023, which was attributed to the robust research and development infrastructure and the growing prevalence of cancer incidence. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer fatalities. There were 403 new cancer cases reported per 100,000 individuals, and 144 individuals passed away from cancer.

The market for nanomedicine in Europe is rapidly expanding as a result of the potential to revolutionize healthcare and the advancements in nanotechnology. This market encompasses the development and utilization of nanoscale materials and devices for the purposes of diagnosis, therapy, and monitoring. The market is expanding as a result of the increasing demand for personalized treatment and the increasing prevalence of chronic diseases. Europe is at the forefront of nanomedicine advancements as a result of its robust healthcare infrastructure and substantial research and development expenditures. Nanoscale imaging techniques, targeted drug delivery methods, and enhanced cancer therapeutics are critical areas of emphasis.

The Asia-Pacific nanomedicine market is a reflection of the increasing interest and investment in advanced healthcare technologies in the region, which is characterized by its rapid evolution. The market is anticipated to experience rapid growth as a result of a variety of factors, such as the increasing prevalence of chronic ailments, the necessity for additional healthcare, and significant advancements in nanotechnology research.

Major Players

Sanofi (France), Johnson & Johnson Services, Inc. (US), Parvus Therapeutics Inc. (US), Nanobiotix (France), Ascendia Pharmaceuticals (US), Bristol-Myers Squibb Company (US), Jazz Pharmaceuticals (Ireland), Cytimmune Sciences, Inc. (US), Nanospectra Biosciences (US), and Pfizer, Inc. (US) are among the key companies in the nanomedicine market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED

3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TYPE

3.8 DATA MODELING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 INCREASING INCIDENCES OF VARIOUS DISEASES ACROSS THE GLOBE

4.2.2 AGREEMENTS ASSOCIATED WITH NANOMEDICINE PRODUCTS DEVELOPMENTS

4.3 RESTRAINTS

4.3.1 HIGH MANUFACTURING COST OF NANOMEDICINE

4.4 OPPORTUNITY

4.4.1 INCREASING NUMBER OF PIPELINE PRODUCTS

5 MARKET FACTOR ANALYSIS

5.1 PORTER’S FIVE FORCES MODEL

5.1.1 THREAT OF NEW ENTRANTS

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 THREAT OF SUBSTITUTES

5.1.4 BARGAINING POWER OF BUYERS

5.1.5 INTENSITY OF RIVALRY

5.2 IMPACT OF COVID-19 ON THE GLOBAL NANOMEDICINE MARKET

6 GLOBAL NANOMEDICINE MARKET, BY MODALITY

6.1 OVERVIEW

6.2 TREATMENTS

6.3 DIAGNOSTICS

7 GLOBAL NANOMEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW

7.2 DRUG DELIVERY

7.3 DIAGNOSTIC IMAGING

7.4 VACCINES

7.5 REGENERATIVE MEDICINE

7.6 IMPLANTS

8 GLOBAL NANOMEDICINE MARKET, BY INDICATION

8.1 OVERVIEW

8.2 ONCOLOGICAL DISEASES

8.3 INFECTIOUS DISEASES

8.4 CARDIOVASCULAR DISEASES

8.5 ORTHOPEDIC DISEASES

8.6 NEUROLOGICAL DISEASES

8.7 UROLOGICAL DISEASES

8.8 OPHTHALMOLOGICAL DISEASES

8.9 IMMUNOLOGICAL DISEASES

8.10 OTHERS

9 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE

9.1 OVERVIEW

9.2 NANOPARTICLES

9.3 NANOSHELLS

9.4 NANOTUBES

9.5 NANODEVICES

9.5.1 ALBUMIN PARTICLES

9.5.2 INORGANIC NANOPARTICLES

9.5.3 LIPID NANOPARTICLE

9.5.4 LIPOSOMES

9.5.5 OTHERS

10 GLOBAL NANOMEDICINE MARKET, BY REGION

10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 US

10.2.2 CANADA

10.3 EUROPE

10.3.1 GERMANY

10.3.2 FRANCE

10.3.3 UK

10.3.4 ITALY

10.3.5 SPAIN

10.3.6 REST OF EUROPE

10.4 ASIA-PACIFIC

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 SOUTH KOREA

10.4.5 AUSTRALIA

10.4.6 REST OF ASIA-PACIFIC

10.5 REST OF THE WORLD

10.5.1 MIDDLE EAST

10.5.2 AFRICA

10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 MARKET SHARE ANALYSIS, 2023

11.3 COMPETITOR DASHBOARD

11.4 PUBLIC PLAYERS STOCK SUMMARY

11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL

11.6.2 PARTNERSHIP/AGREEMENT/COLLABORATION

12 COMPANY PROFILES

12.1 SANOFI

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 JOHNSON & JOHNSON SERVICES, INC.

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGY

12.3 PARVUS THERAPEUTICS INC.

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 KEY STRATEGIES

12.4 NANOBIOTIX

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 KEY STRATEGY

12.5 ASCENDIA PHARMACEUTICAL

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 KEY STRATEGY

12.6 BRISTOL-MYERS SQUIBB COMPANY

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 SWOT ANALYSIS

12.6.6 KEY STRATEGIES

12.7 JAZZ PHARMACEUTICALS

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 CYTIMMUNE SCIENCES, INC.

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS OFFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 KEY STRATEGIES

12.9 NANOSPECTRA BIOSCIENCES

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 KEY STRATEGIES

12.10 PFIZER INC

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 SWOT ANALYSIS

12.10.6 KEY STRATEGIES

13 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 3 GLOBAL NANOMEDICINE MARKET, FOR TREATMENTS, BY REGION, 2019–2032 (USD BILLION)

TABLE 4 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTICS, BY REGION, 2019–2032 (USD BILLION)

TABLE 5 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 6 GLOBAL NANOMEDICINE MARKET, FOR DRUG DELIVERY, BY REGION, 2019–2032 (USD BILLION)

TABLE 7 GLOBAL NANOMEDICINE MARKET, FOR DIAGNOSTIC IMAGING, BY REGION, 2019–2032 (USD BILLION)

TABLE 8 GLOBAL NANOMEDICINE MARKET, FOR VACCINES, BY REGION, 2019–2032 (USD BILLION)

TABLE 9 GLOBAL NANOMEDICINE MARKET, FOR REGENERATIVE MEDICINE, BY REGION, 2019–2032 (USD BILLION)

TABLE 10 GLOBAL NANOMEDICINE MARKET, FOR IMPLANTS, BY REGION, 2019–2032 (USD BILLION)

TABLE 11 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 12 GLOBAL NANOMEDICINE MARKET, FOR ONCOLOGICAL DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 13 GLOBAL NANOMEDICINE MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 14 GLOBAL NANOMEDICINE MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 15 GLOBAL NANOMEDICINE MARKET, FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 16 GLOBAL NANOMEDICINE MARKET, FOR NEUROLOGICAL DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 17 GLOBAL NANOMEDICINE MARKET, FOR UROLOGICAL DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 18 GLOBAL NANOMEDICINE MARKET, FOR OPHTHALMOLOGICAL DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 19 GLOBAL NANOMEDICINE MARKET, FOR IMMUNOLOGICAL DISEASES, BY REGION, 2019–2032 (USD BILLION)

TABLE 20 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 21 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 22 GLOBAL NANOMEDICINE MARKET, FOR NANOPARTICLES, BY REGION, 2019–2032 (USD BILLION)

TABLE 23 GLOBAL NANOMEDICINE MARKET, FOR NANOSHELLS, BY REGION, 2019–2032 (USD BILLION)

TABLE 24 GLOBAL NANOMEDICINE MARKET, FOR NANOTUBES, BY REGION, 2019–2032 (USD BILLION)

TABLE 25 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY REGION, 2019–2032 (USD BILLION)

TABLE 26 GLOBAL NANOMEDICINE MARKET, FOR NANODEVICES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 27 GLOBAL NANOMEDICINE MARKET, FOR ALBUMIN PARTICLES, BY REGION, 2019–2032 (USD BILLION)

TABLE 28 GLOBAL NANOMEDICINE MARKET, FOR INORGANIC NANOPARTICLES, BY REGION, 2019–2032 (USD BILLION)

TABLE 29 GLOBAL NANOMEDICINE MARKET, FOR LIPID NANOPARTICLE, BY REGION, 2019–2032 (USD BILLION)

TABLE 30 GLOBAL NANOMEDICINE MARKET, FOR LIPOSOMES, BY REGION, 2019–2032 (USD BILLION)

TABLE 31 GLOBAL NANOMEDICINE MARKET, FOR OTHERS, BY REGION, 2019–2032 (USD BILLION)

TABLE 32 GLOBAL NANOMEDICINE MARKET, BY REGION, 2019–2032 (USD BILLION)

TABLE 33 NORTH AMERICA: NANOMEDICINE MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 34 NORTH AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 35 NORTH AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 36 NORTH AMERICA: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 37 NORTH AMERICA: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 38 NORTH AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 39 US: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 40 US: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 41 US: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 42 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 43 US: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 44 CANADA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 45 CANADA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 46 CANADA: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 47 US: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 48 CANADA: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 49 EUROPE: NANOMEDICINE MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 50 EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 51 EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 52 EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 53 EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 54 EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 55 GERMANY: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 56 GERMANY: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 57 GERMANY: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 58 GERMANY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 59 GERMANY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 60 FRANCE: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 61 FRANCE: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 62 FRANCE: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 63 FRANCE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 64 FRANCE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 65 UK: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 66 UK: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 67 UK: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 68 UK: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 69 UK: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 70 ITALY: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 71 ITALY: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 72 ITALY: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 73 ITALY: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 74 ITALY: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 75 SPAIN: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 76 SPAIN: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 77 SPAIN: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 78 SPAIN: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 79 SPAIN: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 80 REST OF EUROPE: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 81 REST OF EUROPE: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 82 REST OF EUROPE: NANOMEDICINE MARKET, FOR INDICATION, 2019–2032 (USD BILLION)

TABLE 83 REST OF EUROPE: NANOMEDICINE MARKET, FOR MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 84 REST OF EUROPE: NANOMEDICINE MARKET, FOR NANOPARTICLES, BY TYPE, 2019–2032 (USD BILLION)

TABLE 85 ASIA-PACIFIC: NANOMEDICINE MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 86 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 87 ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 88 ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 89 ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 90 ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 91 CHINA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 92 CHINA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 93 CHINA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 94 CHINA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 95 CHINA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 96 INDIA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 97 INDIA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 98 INDIA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 99 INDIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 100 INDIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 101 JAPAN: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 102 JAPAN: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 103 JAPAN: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 104 JAPAN: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 105 JAPAN: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 106 SOUTH KOREA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 107 SOUTH KOREA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 108 SOUTH KOREA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 109 SOUTH KOREA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 110 SOUTH KOREA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 111 AUSTRALIA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 112 AUSTRALIA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 113 AUSTRALIA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 114 AUSTRALIA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 115 AUSTRALIA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 116 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 117 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 118 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 119 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 120 REST OF ASIA-PACIFIC: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 121 REST OF THE WORLD: NANOMEDICINE MARKET, BY COUNTRY, 2019–2032 (USD BILLION)

TABLE 122 REST OF THE WORLD: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 123 REST OF THE WORLD: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 124 REST OF THE WORLD: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 125 REST OF THE WORLD: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 126 REST OF THE WORLD: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 127 MIDDLE EAST: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 128 MIDDLE EAST: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 129 MIDDLE EAST: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 130 MIDDLE EAST: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 131 MIDDLE EAST: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 132 AFRICA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 133 AFRICA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 134 AFRICA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 135 AFRICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 136 AFRICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 137 LATIN AMERICA: NANOMEDICINE MARKET, BY MODALITY, 2019–2032 (USD BILLION)

TABLE 138 LATIN AMERICA: NANOMEDICINE MARKET, BY APPLICATION, 2019–2032 (USD BILLION)

TABLE 139 LATIN AMERICA: NANOMEDICINE MARKET, BY INDICATION, 2019–2032 (USD BILLION)

TABLE 140 LATIN AMERICA: NANOMEDICINE MARKET, BY MOLECULE TYPE, 2019–2032 (USD BILLION)

TABLE 141 LATIN AMERICA: NANOMEDICINE MARKET, FOR NANOPARTICLE, BY TYPE, 2019–2032 (USD BILLION)

TABLE 142 PUBLIC PLAYERS STOCK SUMMARY

TABLE 143 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 144 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 145 PARTNERSHIP/AGREEMENT/COLLABORATION

TABLE 146 SANOFI: PRODUCTS OFFERED

TABLE 147 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED

TABLE 148 PARVUS THERAPEUTICS INC.: PRODUCT OFFERED

TABLE 149 PARVUS THERAPEUTICS INC. KEY DEVELOPMENTS

TABLE 150 NANOBIOTIX: PRODUCTS OFFERED

TABLE 151 NANOBIOTIX: KEY DEVELOPMENTS

TABLE 152 ASCENDIA PHARMACEUTICAL: PRODUCTS OFFERED

TABLE 153 ASCENDIA PHARMACEUTICALS: KEY DEVELOPMENTS

TABLE 154 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED

TABLE 155 JAZZ PHARMACEUTICALS: PRODUCTS OFFERED

TABLE 156 CYTIMMUNE SCIENCES, INC.: PRODUCTS OFFERED

TABLE 157 CYTIMMUNE SCIENCES, INC.: KEY DEVELOPMENTS

TABLE 158 NANOSPECTRA BIOSCIENCES: PRODCUTS OFFERED

TABLE 159 PFIZER INC: PRODUCT OFFERED

TABLE 160 PFIZER INC: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 GLOBAL NANOMEDICINE MARKET: STRUCTURE

FIGURE 2 GLOBAL NANOMEDICINE MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NANOMEDICINE MARKET

FIGURE 6 GLOBAL NANOMEDICINE MARKET, MODALITY SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 7 GLOBAL NANOMEDICINE MARKET, BY MODALITY, 2023 & 2032 (USD BILLION)

FIGURE 8 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MODALITY, 2023

FIGURE 9 GLOBAL NANOMEDICINE MARKET, APPLICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 10 GLOBAL NANOMEDICINE MARKET, BY APPLICATION, 2023 & 2032 (USD BILLION)

FIGURE 11 GLOBAL NANOMEDICINE MARKET SHARE (%), BY APPLICATION, 2023

FIGURE 12 GLOBAL NANOMEDICINE MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 13 GLOBAL NANOMEDICINE MARKET, BY INDICATION, 2023 & 2032 (USD BILLION)

FIGURE 14 GLOBAL NANOMEDICINE MARKET SHARE (%), BY INDICATION, 2023

FIGURE 15 GLOBAL NANOMEDICINE MARKET, MOLECULE TYPE SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 16 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE, 2023 & 2032 (USD BILLION)

FIGURE 17 GLOBAL NANOMEDICINE MARKET SHARE (%), BY MOLECULE TYPE, 2023

FIGURE 18 GLOBAL NANOMEDICINE MARKET, BY REGION, 2023 & 2032 (USD BILLION)

FIGURE 19 GLOBAL NANOMEDICINE MARKET SHARE, BY REGION, 2023 (% SHARE)

FIGURE 20 NORTH AMERICA MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)

FIGURE 21 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 22 NORTH AMERICA NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 23 EUROPE MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)

FIGURE 24 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 25 EUROPE NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 26 ASIA-PACIFIC MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)

FIGURE 27 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 28 ASIA-PACIFIC NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: NANOMEDICINE MARKET, 2019-2032 (USD BILLION)

FIGURE 30 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 31 REST OF THE WORLD NANOMEDICINE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 1 NANOMEDICINE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023

FIGURE 2 COMPETITOR DASHBOARD: NANOMEDICINE MARKET

FIGURE 3 SANOFI: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 4 SANOFI: SWOT ANALYSIS

FIGURE 5 JOHNSON & JOHNSON SERVICES, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 6 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS

FIGURE 7 NANOBIOTIX: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 8 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 9 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS

FIGURE 10 JAZZ PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 11 JAZZ PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 12 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 PFIZER INC: SWOT ANALYSIS

医療・医薬の最新記事8件